ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced hodgkin's lymphoma: Results from the HD2000 gruppo italiano Per lo studio dei linfomi trial

Journal of Clinical Oncology

Volumn 27, Issue 5, 2009, Pages 805-811

  Federico, Massimo ^a,b   Luminari, Stefano ^c   Iannitto, Emilio ^c   Polimeno, Giuseppe ^c   Marcheselli, Luigi ^c   Montanini, Antonella ^c   Sala, Antonio La ^c   Merli, Francesco ^c   Stelitano, Caterina ^c   Pozzi, Samantha ^c   Scalone, Renato ^c   Renzo, Nicola Di ^c   Musto, Pellegrino ^c   Baldini, Luca ^c   Cervetti, Giulia ^c   Angrilli, Francesco ^c   Mazza, Patrizio ^c   Brugiatelli, Maura ^c   Gobbi, Paolo G ^c  

^a Dipartimento di Oncologia ed Ematologia   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; LOMUSTINE; MELPHALAN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; VINDESINE;

ADULT; ADVANCED CANCER; ALOPECIA; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CANDIDIASIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; INFECTION; LEUKOPENIA; LIVER DYSFUNCTION; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; PAIN; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS INFECTION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CARBOPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

EID: 59949089090     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.0910     Document Type: Article

References (30)

1. Bonadonna G, Zucali R, Monfardini S, et al: Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 36:252-259, 1975
2. Canellos GP, Anderson JR, Propert KJ, et al: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478-1484, 1992
3. Santoro A, Bonadonna G, Valagussa P, et al: Long-term results of combined chemotherapy- radiotherapy approach in Hodgkin's disease: Superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 5:27-37, 1987
4. Horning SJ, Hoppe RT, Breslin S, et al: Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: Mature results of a prospective clinical trial. J Clin Oncol 20:630-637, 2002
5. Gobbi PG, Pieresca C, Federico M, et al: MOPP/EBV/CAD hybrid chemotherapy with or without limited radiotherapy in advanced or unfavorably presenting Hodgkin's disease: A report from the Italian Lymphoma Study Group. J Clin Oncol 11:712-719, 1993
6. Gobbi PG, Pieresca C, Ghirardelli ML, et al: Long-term results from MOPPEBVCAD chemotherapy with optional limited radiotherapy in advanced Hodgkin's disease. Blood 91:2704-2712, 1998
7. Canellos GP, Gollub J, Neuberg D, et al: Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up. Ann Oncol 14:268-272, 2003
8. Viviani S, Bonfante V, Santoro A, et al: Longterm results of an intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin's disease. Cancer J Sci Am 5:275-282, 1999
9. Martinelli G, Cocorocchio E, Peccatori F, et al: ChlVPP/ABVVP,a first line'hybrid'combination chemotherapy for advanced Hodgkin's lymphoma: A retrospective analysis. Br J Haematol 125:584-589, 2004
10. Diehl V, Franklin J, Pfreundschuh M, et al: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348:2386-2395,2003
11. Lister TA, Crowther D, Sutcliffe SB, et al: Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 7:16301636, 1989
12. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
13. Hryniuk WM: Average relative dose intensity and the impact on design of clinical trials. Semin Oncol 14:65-74, 1987
14. De Vita VT Jr, Hubbard SM, Longo DL: The chemotherapy of lymphomas: Looking back, moving forward-the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res 47:5810-5824, 1987
15. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on advanced Hodgkin's disease. N Engl J Med 339:1506-1514, 1998
16. Sankoh AJ, Huque MF, Dubey SD: Some comments on frequently used multiple endpoint adjustment methods in clinical trials. Stat Med 16: 2529-2542, 1997
17. Diehl V, Franklin J, Hasenclever D, et al: BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: Interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 16:3810-3821, 1998
18. Altman DG, Schulz KF, Moher D, et al: The revised CONSORT statement for reporting randomized trials: Explanation and elaboration. Ann Intern Med 134:663-694, 2001
19. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
20. Cox D: Regression models and life tables. J R Stat Soc B 34:187-202, 1972
21. Schoenfeld D: Partial residuals for proportional hazard regression model. Biometrika 69:239-241, 1982
22. Armitage P, Berry G: Statistical Methods in Medical Research (ed 2). Oxford, United Kingdom, Blackwell, 1987, pp 125-132
23. Engert A, Franklin J, Diehl V: Long-term follow-up of BEACOPP escalated chemotherapy in patients with advanced-stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group, American Society of Hematology, Blood, 110:11, 2007 (abstr 211)
24. Connors JM: Evolving approaches to primary treatment of Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 239-244, 2005
25. Johnson PW, Radford JA, Cullen MH, et al: Comparison of ABVD and alternating or hybrid multi- drug regimens for the treatment of advanced Hodgkin's lymphoma: Results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol 23:9208-9218, 2005
26. Duggan DB, Petroni GR, Johnson JL, et al: Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an intergroup trial. J Clin Oncol 21:607-614, 2003
27. Gobbi PG, Levis A, Chisesi T, et al: ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: Final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 23:9198-9207, 2005
28. Hutchings M, Loft A, Hansen M, et al: FDG- PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:52-59, 2006
29. Gallamini A, Rigacci L, Merli F, et al: The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 91:475-481, 2006
30. Gallamini A, Hutchings M, Rigacci L, et al: Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study. J Clin Oncol 25:3746-3752, 2007